Biotech Values

[DewDiligence]

Re: PFE

>Not that it matters, but I do not agree with that assessment.<

If you are saying that PFE’s late-stage pipeline is not that good relative to the size of the company, I would agree with that.

However, in the context of Dubi’s post, which suggested that PFE must do something dramatic (such as acquiring TEVA) to make any headway with investors, I think PFE’s three near-term launches (Exubera, Sutent, Indiplon) do make PFE’s late-stage pipeline “one of the best” in an absolute sense.

--
I’d be interested in your opinion as to whether PFE would be more inclined to pay $30B or so to acquire TEVA (as Dubi suggested), or roughly $15B (give or take a few billion) to acquire each of two mid-cap companies such as AGN, BIIB, and FRX (as I suggested).